✦ LIBER ✦

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

✍ Scribed by Gautschi, Oliver; Dingemans, Anne-Marie; Crowe, Susanne; Peters, Solange; Roder, Heinrich; Grigorieva, Julia; Roder, Joanna; Zappa, Francesco; Pless, Miklos; Brutsche, Martin; Baty, Florent; Bubendorf, Lukas; Hsu Schmitz, Shu-Fang; Na, Kyung-Jae; Carbone, David; Stahel, Rolf; Smit, Egbert

Book ID: 119320976
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 283 KB
Volume: 79
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.10.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN43 COST COMPARISON OF ERLOTINIB VERSU

PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY

✍ S Ravera; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN44 COST COMPARISON OF ERLOTINIB VERSU

PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN

✍ J Castro de Carpeño; AJ Castro-Gómez; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

P-482 Activity of topotecan in patients

P-482 Activity of topotecan in patients with advanced non-small cell lung cancer pre-treated with platinum and taxanes: Results of the first analysis

✍ Fernández, Y.; Esteban, E.; Villanueva, N.; Palacio, I.; Muñiz, I.; Jimenez, P.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

First-cycle rash and survival in patient

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

✍ Ulrich Gatzemeier; Joachim von Pawel; Ihor Vynnychenko; Petr Zatloukal; Filippo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 220 KB

PCN43 THE COST OF TREATING GRADE 3/4 ADV

PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

✍ C Chouaid; A Vergnenegre; M Brunner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PD-068 An exploratory analysis of a phas

PD-068 An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel

✍ Bunn, P.; Rosell, R.; Fossella, F.; Perry, M.; Stahel, R.; Barata, F.; Nguyen, B 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB